In times of situational therapeutic impasse, health care professionals
(HCPs) are under pressure to conduct off-label, unlicensed and
compassionate drug use--generally summarized under the term non-licensed
drug use (NDU). Liability, contractual and penal risks pose a problem
when treating a patient in a non-licensed way. There is a knowledge gap
about institutional and governmental methods to resolve these problems.
Different countries have developed strategies to manage NDU. Vanessa
Platé gives a comprehensive overview of practices Canada, the U.S., the
U.K., Japan, France, Germany, Switzerland, Austria, and the
transnational E.U. A must-read for everyone interested in the discussion
on how to administer the best treatment, especially regarding early
access to yet unapproved treatments.